Updated:
Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited was founded in 2015 by Dr. Thomas Rademacher, drawing on decades of immunology research at University College London.
Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited was founded in 2015 by Dr. Thomas Rademacher, drawing on decades of immunology research at University College London. The entity operates as a single-family office dedicated to vaccine development, with its scientific core rooted in synthetic peptide technology that aims to bypass traditional cold-chain logistics. Wealth originates from the Rademacher family's entrepreneurial activities in biotechnology. The firm's strategy focuses on developing T-cell-based vaccines for infectious diseases, covering preclinical through Phase I and Phase II clinical trials. Its pipeline includes vaccine candidates against dengue, Zika, and influenza, with a platform that claims room-temperature stability as a differentiator (per the firm's official communications). The geographic footprint spans the UK and Switzerland, with clinical trial sites in Europe and Asia. Deployment remains tightly concentrated on R&D, with no disclosed AUM or external capital raised. The firm operates a small team of scientists and executives, centered in London. May 2025: Advanced its dengue vaccine candidate into Phase I/II trials in Switzerland (per public record). Emergex's structural differentiator lies in its family-office governance married to a single-asset vaccine pipeline — an unusual architecture that avoids the diversification typical of most multi-family offices. This concentration on one scientific platform creates a high-risk, high-upside mandate tied entirely to clinical success.
General information
Firm type
Single Family Office
Year founded
2015
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Dr. Julian Hickling
CEO
Dr. Thomas Rademacher
Co-Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Emergex Vaccines Holding Limited?
Investment decisions are led by Dr. Thomas Rademacher, the co-founder and scientific principal. Day-to-day operations are managed by CEO Dr. Julian Hickling. The firm's mandate is scientific rather than financial, with no external investment committee disclosed (per public record).
Is Emergex structured as a single family office or a venture capital firm?
It is structured as a single-family office, not a venture capital firm. The entity exists to fund and develop its own vaccine pipeline, not to invest in external companies. It holds no outside assets beyond its intellectual property and clinical-stage candidates (per public record).
What investment stages does Emergex typically target?
The firm targets early-stage vaccine development exclusively: preclinical through Phase II clinical trials. It does not participate in seed, growth, or public market investing. All capital is allocated to R&D, clinical manufacturing, and trial operations for its synthetic peptide platform.
Which sectors does Emergex explicitly avoid?
The firm avoids all sectors outside of infectious disease vaccines. It has no exposure to oncology, rare diseases, therapeutic modalities, or any non-vaccine biotech. Its focus is limited to T-cell-based vaccine candidates against dengue, Zika, and influenza (per the firm's official communications).
Does Emergex maintain philanthropic structures?
Public records show no separate philanthropic foundation tied to Emergex Vaccines Holding Limited. The Rademacher family may maintain private charitable activities, but these are not disclosed within the corporate structure of the holding company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: